S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma

S. Uddin, A. Hussain, M. Ahmed, A. Belgaumi, F. Al-Dayel, D. Ajarim, P. Bavi, K. S. Al-Kuraya

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)


S-phase kinase protein 2 (SKP2), an F-box protein, targets cell-cycle regulators including cycle-dependent kinase inhibitor p27KiP1 via ubiquitin-mediated degradation. SKP2 is frequently overexpressed in a variety of cancer cells and has been implicated in oncogenesis; however, its role in diffuse large B-cell lymphoma (DLBCL) has not been elucidated. Therefore, we investigated the role of SKP2 and its ubiquitin-proteasome pathway in a large series (301) of DLBCL patient samples and a panel of DLBCL cell lines. Using immunohistochemistry, SKP2 was detected in 41.6% of DLBCL tumours and was inversely associated with p27Kip1 protein level. The DLBCL subset with high SKP2 and low p27Kip1 showed a strong correlation with the proliferating index marker Ki-67 (p < 0.0001) and also with the germinal centre phenotype (p = 0.0147). Treatment of DLBCL cell lines with bortezomib or expression of SKP2-specific siRNA causes down-regulation of SKP2 and accumulation of p27Kip1, leading to suppression of growth by inducing apoptosis. Furthermore, treatment of DLBCL cells with bortezomib causes apoptosis via involving the mitochondrial pathway and activation of caspases. Finally, treatment of DLBCL cells with bortezomib down-regulated the expression of XIAP, cIAP1, and survivin. Altogether, these results suggest that SKP2 and the ubiquitin-proteasome pathway may be a potential target for therapeutic intervention in DLBCL.

Original languageEnglish
Pages (from-to)483-494
Number of pages12
JournalJournal of Pathology
Issue number4
Publication statusPublished - Dec 2008
Externally publishedYes


  • Apoptosis
  • NHL therapy
  • SKP2
  • Tissue microarray


Dive into the research topics of 'S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this